ticker
stringlengths 2
5
| disease
stringlengths 3
196
| stage
stringclasses 15
values | date
stringlengths 19
19
| catalyst
stringlengths 18
760
| label
int64 -1
1
|
|---|---|---|---|---|---|
IMGN
|
Ovarian cancer
|
Phase 1/2
|
2022-09-29 00:00:00
|
Phase 1/2 data reported an ORR of 44%, a median DOR of 11.8 months, and median PFS of 8.2 months, noted September 29, 2022.
| 0 |
TNXP
|
Major depressive disorder (MDD)
|
Phase 2
|
2023-11-01 00:00:00
|
Phase 2 topline data reported that the trial did not meet its primary endpoint, noted November 1, 2023.
| 1 |
VTGN
|
Adjunctive Treatment Major Depressive Disorder
|
Phase 2
|
2019-11-14 00:00:00
|
Phase 2 data did not meet primary endpoint - November 14, 2019.
| 1 |
GLPG
|
B-cell malignancies, Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
|
Phase 1/2
|
2023-06-09 00:00:00
|
Phase 1/2 data presented at EHA showed that based on current results (n=7). For all 7 pts, GLPG5201 was successfully manufactured at the PoC and administered as a fresh product, with a median vein-to-vein time of 7 days. Rapid complete responses have been observed with a 100% ORR in a heavily pre-treated pt population. Ph 1 recruitment is ongoing to establish a recommended dose for Phase 2, noted June 9, 2023.
| 1 |
BBIO
|
Achondroplasia
|
Phase 2
|
2023-06-20 00:00:00
|
Phase 2 cohort 5 data reported at ENDO showed that at the Cohort 5 dose level resulted in a significant and robust increase in AHV compared to BL, with a change of +3.38cm/year, noted June 20, 2023.
| 1 |
HEPA
|
NASH and Liver Cancer
|
Phase 2a
|
2022-01-08 00:00:00
|
Phase 2a data reported that treatment was well-tolorated with ALT decreased in 50%, 67%, and 87% of the subjects in the placebo, 75 mg, and 225 mg cohorts, respectively, noted January 8, 2022.
| 1 |
BMY
|
Non-transfusion-dependent beta-thalassemia
|
Phase 2
|
2021-06-11 00:00:00
|
Phase 2 data presented at EHA meeting June 11, 2021. 77.7% of patients achieved a hemoglobin increase compared to 0% in the placebo arm.
| 1 |
BMY
|
Non-Small Cell Lung Cancer (NSCLC)
|
Approved
|
2022-04-11 00:00:00
|
Approved April 11, 2022.
| 1 |
JNJ
|
Multiple sclerosis
|
Approved
|
2015-04-16 00:00:00
|
Approved April 16 2015.
| 1 |
PFE
|
Multiple Myeloma
|
Approved
|
2023-08-14 00:00:00
|
FDA Approved on August 14, 2023.
| 1 |
INVA
|
Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter)
|
Approved
|
2023-05-24 00:00:00
|
Approved May 24, 2023.
| 1 |
MTEM
|
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
|
Phase 2
|
2021-04-05 00:00:00
|
Development to be discontinued - April 5, 2021.
| -1 |
JNJ
|
Multiple myeloma - candidates for autologous stem cell transplant (ASCT)
|
Approved
|
2019-09-26 00:00:00
|
FDA Approval announced September 26, 2019.
| 1 |
AMRN
|
Covid-19
|
Phase 3
|
2021-11-16 00:00:00
|
Phase 3 trial did not met the primary or secondary endpoints, noted November 16, 2021.
| 0 |
RCUS
|
Metastatic castrate-resistant prostate cancer (mCRPC)
|
Phase 1/2
|
2023-08-07 00:00:00
|
Phase 1/2 trial is not expected to demonstrate sufficient clinical benefit in castrate resistant prostate cancer to warrant further investment, noted August 7, 2023.
| 1 |
ITCI
|
Bipolar depression
|
Phase 3
|
2019-07-08 00:00:00
|
Phase 3 trial did not meet primary endpoint - July 8, 2019.
| 1 |
PTGX
|
Polycythemia vera
|
Phase 2
|
2023-11-02 00:00:00
|
Phase 2 data from abstract reported that treatment resulted in consistent maintenance of hematocrit below 45% and an overall decrease in erythrocyte counts, noted November 2, 2023.
| 1 |
INCY
|
Myelofibrosis
|
Approved
|
2011-11-16 00:00:00
|
Approved November 16, 2011.
| 1 |
LPCN
|
Testosterone replacement therapy (TRT)
|
Approved
|
2022-03-29 00:00:00
|
Approved March 29, 2022.
| 1 |
VBIV
|
Hepatitis B vaccine
|
Phase 3
|
2022-09-21 00:00:00
|
Additional Phase 3 data reported that treatment may be effective only in low level HBsAg carriers with a low tolerizing effect of HBsAg, noted September 21, 2022.
| 1 |
CYTH
|
Niemann-Pick Disease Type C
|
Phase 1
|
2022-10-18 00:00:00
|
Phase 1 data showed that treatment overcomes the NPC1 defect by removing trapped cholesterol from cells both systemically and in the central nervous system (CNS), noted October 18, 2022.
| 1 |
PSTV
|
Leptomeningeal metastases (LM)
|
Phase 1/2
|
2023-11-03 00:00:00
|
FDA granted Orphan Drug Designation (ODD), noted November 3, 2023.
| 0 |
RHHBY
|
Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 3
|
2022-12-12 00:00:00
|
Phase 3 results reported that trial met primary endpoints, noted December 12, 2022.
| 0 |
EDIT
|
Sickle Cell Disease
|
Phase 1/2
|
2023-06-09 00:00:00
|
Phase 1/2 data presented at EHA reported that all five patients treated with EDIT-301 successfully engrafted and all four RUBY patients treated are free of vaso-occlusive events since infusion, noted June 9, 2023.
| 1 |
MRNA
|
Respiratory syncytial virus (RSV) vaccine
|
BLA Filing
|
2023-07-05 00:00:00
|
BLA rolling submission, noted July 5, 2023.
| 0 |
MRK
|
Pulmonary arterial hypertension (PAH)
|
Phase 2
|
2021-05-19 00:00:00
|
Phase 2 update at the American Thoracic Society 2021 International Conference May 19, 2021. Generally well tolerated, improvements in resting and exercise hemodynamics at week 24 shown.
| 1 |
MRK
|
Personalized cancer vaccine, high-risk melanoma
|
Phase 2
|
2023-10-23 00:00:00
|
Phase 2 additional data presented at ESMO reported that local recurrence was more common in MRs; MNRs had more distant events. This trend was supported by stronger separation in DMFS vs RFS between MRs and MNRs, noted October 23, 2023.
| 1 |
MRK
|
Complicated urinary tract infections (cUTI) and Complicated intra-abdominal infections (cIAI)
|
Approved
|
2019-07-17 00:00:00
|
FDA Approval announced July 17, 2019.
| 1 |
AUTL
|
B-Cell Acute Lymphoblastic Leukemia
|
Phase 2
|
2023-06-02 00:00:00
|
Phase 2 safety and efficacy data presented at ASCO showed that 76% of patients treated achieved a response (CR/CRi), primary endpoint has been met based on previously communicated interim analysis, noted June 2, 2023
| 1 |
GRTX
|
Pancreatic cancer
|
Phase 1/2
|
2021-09-08 00:00:00
|
Phase 1/2 trial final results announced - GC4419 was well tolerated, with similar rates of early and late adverse events in the active and placebo arms September 8, 2021.
| 1 |
NBIX
|
Parkinson's Disease
|
Phase 2
|
2020-12-22 00:00:00
|
Phase 2 trial placed on clinical hold - December 22, 2020.
| 0 |
MOR
|
Psoriatic Arthritis
|
Approved
|
2020-07-14 00:00:00
|
FDA Approval announced July 14, 2020.
| 1 |
AVRO
|
Gaucher disease
|
Phase 1/2
|
2021-10-19 00:00:00
|
Phase 1/2 safety data reported no SAEs and no AEs for more than 14 months post-treatment, noted October 19, 2021.
| 1 |
ABBV
|
Atopic dermatitis
|
Approved
|
2022-01-14 00:00:00
|
Approved January 14, 2022.
| 1 |
ACOR
|
Parkinson’s disease (PD)
|
Phase 3
|
2017-11-15 00:00:00
|
Phase 3 data due 1Q 2018. Noted November 15, 2017 seven cases of sepsis, five of which were fatal.
| 0 |
EBS
|
Opioid overdose
|
Approved
|
2023-03-29 00:00:00
|
Approved March 29, 2023.
| 1 |
RIGL
|
COVID-19
|
Phase 2
|
2021-04-13 00:00:00
|
Phase 2 trial met primary endpoint of safety - April 13, 2021.
| 0 |
MRTX
|
MTAP-deleted cancers
|
Phase 1
|
2023-08-08 00:00:00
|
Phase 1 data reported a safety profile and early signs of clinical activity, noted August 8, 2023.
| 0 |
PFE
|
Biosimilar bevacizumab
|
Approved
|
2019-06-28 00:00:00
|
FDA Approval announced June 28, 2019.
| 1 |
BMY
|
RET-altered NSCLC
|
Phase 1/2
|
2021-04-05 00:00:00
|
Phase 1/2 interim data noted 3/14 partial responses - April 5, 2021.
| 0 |
AZN
|
Lung cancer
|
Phase 3
|
2018-11-16 00:00:00
|
Overall survival data also did not meet primary endpoint - November 16, 2018.
| 1 |
LLY
|
COVID-19 antibody
|
Approved
|
2022-02-11 00:00:00
|
EUA granted by FDA February 11, 2022.
| 0 |
MRK
|
Non-small cell lung cancer (NSCLC)
|
Approved
|
2019-04-11 00:00:00
|
FDA Approval announced April 11, 2019.
| 1 |
MESO
|
Inflammatory bowel disease (IBD), Ulcerative colitis or Crohn’s colitis
|
Phase 1/2
|
2022-02-20 00:00:00
|
Phase 1/2 interim analysis reported that all ulcerative colitis patients had improved clinical and endoscopy scores within two weeks, and all Crohn’s colitis patients showed treatment remissions or responses by three months, noted February 20, 2022.
| 1 |
BCRX
|
Paroxysmal nocturnal hemoglobinuria (PNH), Healthy Volunteers
|
Phase 1
|
2023-10-26 00:00:00
|
Phase 1 PoC trial with PNHl initiated, noted October 26, 2023.
| 0 |
MRKR
|
Lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatment
|
Phase 1
|
2023-09-11 00:00:00
|
Phase 1 clinical update showed that patients with Non-Hodgkin's Lymphoma who relapsed after anti-CD19 CAR T cell therapy tolerated initial dose level well and achieved complete response after MT-601 treatment, noted September 11, 2023.
| 1 |
ONCY
|
Pancreatic cancer
|
Phase 2
|
2021-05-20 00:00:00
|
Phase 2 data in ASCO abstract noted response rate 1/12 (8.3%); stable disease 42%.
| 0 |
MRK
|
BRCAm HER2-negative breast cancer
|
Approved
|
2022-03-11 00:00:00
|
Approved March 11, 2022.
| 1 |
BMY
|
Tumors harboring ALK, ROS1, or NTRK1-3 alterations
|
Phase 1/2
|
2021-10-23 00:00:00
|
Phase 1/2 early clinical data demonstrated confirmed responses in (3/4) TKI-naïve patients, noted October 23, 2021.
| 1 |
RHHBY
|
Autosomal Dominant Alzheimer's Disease (ADAD
|
Phase 3
|
2022-08-02 00:00:00
|
Additional Phase 3 data reported that cognitive test scores of API ADAD composite 22.9%, FCSRT 19.9% and RBANS total score 43.8%, noted August 2, 2022.
| 0 |
TSVT
|
Newly Diagnosed Multiple Myeloma
|
Phase 2a
|
2022-12-10 00:00:00
|
Cohort 2a efficacy and safety data presented at ASH demonstrated complete and durable responses in a significant proportion of patients, noted on December 10, 2022.
| 1 |
BIIB
|
Rheumatoid arthritis (RA)
|
Approved
|
2023-09-29 00:00:00
|
FDA Biosimilar of ACTEMRA approved on September 29, 2023.
| 1 |
BGNE
|
HER2-amplified biliary tract cancers
|
Phase 2
|
2023-06-05 00:00:00
|
Phase 2 pivotal trial recruitment completed, noted April 28, 2022. Phase 2 full data presented at ASCO reported a confirmed objective response rate (cORR) of 41.3%, median duration of response (DOR) of 12.9 months, and median progression-free survival (PFS) of 5.5 months, noted June 5, 2023.
| 1 |
AVIR
|
COVID-19
|
Phase 2
|
2021-10-19 00:00:00
|
Phase 2 trial did not meet primary endpoint, noted October 19, 2021.
| 1 |
VCYT
|
Prostate cancer
|
Phase 3
|
2023-10-04 00:00:00
|
Phase 3 trial validation of a genomic classifier presented at the ASTRO meeting noting that only the Decipher Prostate risk score was independently associated with metastasis-free survival (MFS; HR 1.12, 95% CI) and distant metastasis (DM; sHR 1.22, 95% CI), compared to standard risk factors including Gleason score, T-stage and prostate-specific antigen (PSA) level, noted October 4, 2023.
| 1 |
JSPR
|
Sickle Cell Disease and Beta Thalassemia
|
Phase 1/2
|
2023-02-16 00:00:00
|
Phase 1/2 follow up data reported that two sickle cell disease participants have achieved 100% donor myeloid chimerism through 100 days follow-up, noted February 16, 2023.
| 1 |
MRK
|
Heart Failure
|
Approved
|
2021-01-20 00:00:00
|
FDA approval announced January 20, 2021.
| 1 |
CUE
|
Wilms' Tumor (WT1)-expressing cancers
|
Phase 1
|
2023-11-03 00:00:00
|
Phase 1 data presented at SITC demonstrated a 75%-80% DCR at the 4mg/kg and 2mg/kg doses respectively with two patients demonstrating tumor reductions of -30% and -29%, noted November 3, 2023.
| 1 |
RLYB
|
Paroxysmal nocturnal hemoglobinuria (PNH); Generalized Myasthenia Gravis (gMG)
|
Phase 1
|
2023-09-03 00:00:00
|
Phase 1 multiple ascending trial data reported maximum exposures of greater than 1 µM and 3 µM, respectively, and greater than 99% reductions in free C5 concentrations, noted September 3, 2023.
| 1 |
BHVN
|
Amyotrophic lateral sclerosis (ALS)
|
CRL
|
2019-07-19 00:00:00
|
CRL issued July 19, 2019.
| 0 |
SGEN
|
HER2 amplified metastatic colorectal cancer
|
Approved
|
2023-01-19 00:00:00
|
Approved January 19, 2023.
| 1 |
JNJ
|
Multiple Myeloma
|
Phase 3
|
2023-06-05 00:00:00
|
Phase 3 results shared at ASCO demonstrated a statistically significant improvement in progression-free survival, with a hazard ratio of 0.26, noted June 5, 2023
| 1 |
VKTX
|
Non-alcoholic steatohepatitis (NASH) and fibrosis
|
Phase 2b
|
2023-05-16 00:00:00
|
Phase 2b data reported that trial met primary endpoint, noted May 16, 2023.
| 0 |
RCKT
|
Glaucoma
|
Phase 2
|
2017-07-07 00:00:00
|
Phase 2 trial failed - noted July 7, 2017.
| -1 |
FBRX
|
Atopic Dermatitis
|
Phase 2
|
2021-09-02 00:00:00
|
Phase 2 failed to meet primary endpoint September 02, 2021.
| 1 |
RHHBY
|
Neovascular age related macular degeneration (nAMD)
|
Phase 3
|
2021-01-25 00:00:00
|
Phase 3 trial met primary endpoint - January 25, 2021.
| 0 |
ARCT
|
COVID-19 variant vaccine
|
Phase 1/2
|
2022-01-24 00:00:00
|
Additional Phase 1/2 data reported neutralization against several variants of concern after day 15 and 29, noted January 24, 2022.
| 0 |
WVE
|
Huntington’s disease
|
Phase 1/2
|
2021-03-29 00:00:00
|
Phase 1/2 data showed no statistically significant change in mutant huntingtin protein (mHTT). Development to be stopped
| 1 |
DBVT
|
Peanut allergy - ages 4 to 11 years
|
CRL
|
2020-08-04 00:00:00
|
CRL issued August 4, 2020
| 0 |
VRNA
|
COVID-19
|
Phase 2
|
2021-04-23 00:00:00
|
Phase 2 top-line data released April 23, 2021 - safe and well tolerated. One patient death was reported in the ensifentrine treatment group.
| 1 |
BHVN
|
Multiple system atrophy (MSA)
|
Phase 3
|
2021-09-27 00:00:00
|
Phase 3 trial did not met primary or secondary endpoints, noted September 27, 2021.
| 0 |
NBIX
|
Negative symptoms of schizophrenia
|
Phase 2
|
2021-03-02 00:00:00
|
Phase 2 trial did not meet primary endpoint - March 2, 2021.
| 1 |
ETON
|
Nutritional requirements for patients with liver disease
|
Approved
|
2022-04-11 00:00:00
|
Approved April 11, 2022.
| 1 |
TERN
|
Nonalcoholic steatohepatitis (NASH)
|
Phase 2a
|
2021-11-12 00:00:00
|
Phase 2a safety and efficacy clinical data reported no differences from placebo in percentage change in low density lipoprotein (LDL) cholesterol or high density lipoprotein (HDL) cholesterol. Reductions in alanine transaminase (ALT) and MRI proton density fat fraction (MRI-PDFF) were reported in the 10 and 15 mg groups, and significant reductions in gamma-glutamyl transferase (GGT) in all dose groups, noted November 12, 2021.
| 1 |
IMVIQ
|
Ovarian Cancer
|
Phase 1/2
|
2022-06-06 00:00:00
|
Results from Phase 1 and Phase 2 expansion cohort presented at ASCO reported that G3/G2 immune-related AE and injection site reactions were observed in 1/1 and 1/3 pts treated at DL1, and in 1/0 and 2/2 pts at DL2, respectively. At Phase 1, one patient with MSI-High clear cell subtype had an ongoing CR after 26 months of follow-up, 2 patients had PR and 6 SD. There were 1 PR and 3 SD on P2EC, of which 1 and 2, respectively, achieved response greater than 12 weeks, noted June 6, 2022.
| 1 |
GILD
|
Urothelial Cancer
|
Approved
|
2021-04-13 00:00:00
|
FDA approval announced April 13, 2021.
| 1 |
BMY
|
Chronic lymphocytic leukemia (CLL)
|
Phase 1/2
|
2023-06-06 00:00:00
|
Phase 1/2 data presented at ASCO reported that the primary endpoint of CR/CRi rate was met at 18.4%, and the ORR was 42.9% and was not statistically significant, noted June 6, 2023.
| 1 |
GHRS
|
Treatment-Resistant Depression (TRD)
|
Phase 2
|
2021-12-06 00:00:00
|
Phase 2 trial met primary and secondary endpoints, noted December 6, 2021.
| 0 |
BTAI
|
Neuroendocrine Prostate Cancer (NEPC)
|
Phase 2a
|
2023-01-11 00:00:00
|
Phase 2a data reported that combination with pembrolizumab has demonstrated an encouraging response rate, noted January 11, 2023.
| 1 |
LLY
|
Crohn's disease
|
Phase 3
|
2023-10-12 00:00:00
|
Phase 3 trial met the co-primary and all major secondary endpoints, noted October 12, 2023.
| 0 |
AMTI
|
Pouchitis
|
Phase 2
|
2023-03-03 00:00:00
|
Additional Phase 3 data demonstrated oral's gut-restricted profile with tissue-level pharmacodynamics (PD) effects and no systemic exposure by design. Translational analysis reveals IL-10 biological responses in 3mg and 10mg dose arms, noted March 3, 2023.
| 1 |
AMGN
|
Solid tumors with MTAP deletion, NSCLC
|
Phase 1
|
2022-03-15 00:00:00
|
Phase 1 updated data reported no drug-related SAE's or observed dose limiting toxicity (DLT) through Cohort 5, noted March 15, 2022.
| 1 |
ALNY
|
Gout
|
Phase 1
|
2022-12-15 00:00:00
|
Phase 1 pharmacodynamic data suggest extrahepatic contributes significantly to serum urate in humans, noted December 15, 2022.
| 0 |
BYSI
|
Non small cell lung cancer
|
Phase 3
|
2022-12-13 00:00:00
|
Additional data reported that plinabulin demonstrated a superior benefit for Gr4N, Gr3/4N, all GrN and DSN compared to the control, noted December 13, 2022.
| 1 |
LLY
|
Hemophilia A
|
Phase 1/2
|
2021-07-09 00:00:00
|
Phase 1/2 clinical hold announced July 9, 2021.
| 0 |
KRYS
|
Alpha-1 antitrypsin deficiency (AATD)
|
Phase 1a
|
2023-09-05 00:00:00
|
FDA granted Orphan Drug Designation, noted September 5, 2023.
| 0 |
KZIA
|
Glioblastoma multiforme
|
Phase 2
|
2022-06-03 00:00:00
|
Phase 2 final data presented at ASCO reported that the median overall survival (OS) in the intent-to-treat (ITT) population was 15.7 months, compared to 12.7 months which was historically reported with temozolomide in this patient group. Median progression-free survival (PFS) in the ITT population was 8.6 months, noted June 3, 2022.
| 1 |
OCGN
|
Graft Versus Host Disease
|
Phase 3
|
2020-06-01 00:00:00
|
Phase 3 trial stopped early due to insufficient efficacy.
| -1 |
RVMD
|
Pancreatic cancer, non-small cell lung cancer (NSCLC), and colorectal cancer.
|
Phase 1
|
2023-09-19 00:00:00
|
Phase 1 dosing initiated, noted Septemeber 19, 2023.
| 0 |
BCRX
|
Hereditary Angioedema
|
Phase 2
|
2023-05-07 00:00:00
|
Additional long-term 96 weeks at 150mg data reported that the attack-free status was consistently high with ORLADEYO 150 mg regardless of patients' age, gender and prior prophylactic treatment, noted May 7, 2023.
| 1 |
AMGN
|
Uncontrolled Gout
|
Approved
|
2022-07-08 00:00:00
|
Approved July 8, 2022.
| 1 |
CINC
|
Uncontrolled Hypertension (rHTN)
|
Phase 1
|
2022-11-28 00:00:00
|
Phase 1 topline data reported that trial did not meet primary endpoint, noted November 28, 2022.
| 1 |
KURA
|
Head and neck squamous cell carcinomas (HNSCC)
|
Phase 2
|
2023-10-21 00:00:00
|
Phase 2 data presented at ESMO reported that the Tipifarnib ORR was higher in 2L setting than 3L+ setting (29% vs. 15%), noted October 21, 2023.
| 1 |
SMMT
|
C. difficile infection (CDI)
|
Phase 3
|
2022-10-20 00:00:00
|
Phase 3 trial results reported that treatment was numerically higher sustained clinical response rate (73.0% vs 70.7%) than vancomycin, but did not achieve the pre-specified superiority endpoint, noted October 20, 2022.
| 1 |
PXMD
|
Human African Trypanosomiasis (HAT)
|
Phase 2b
|
2023-07-24 00:00:00
|
Phase 2b trial met its primary endpoint, noted July 24, 2023.
| 0 |
LIAN
|
Hypertrophic cardiomyopathy (HCM)
|
Approved
|
2022-04-28 00:00:00
|
Approved April 28, 2022.
| 1 |
MIRM
|
Progressive Familial Intrahepatic Cholestasis (PFIC)
|
Phase 3
|
2022-10-24 00:00:00
|
Phase 3 top-line data reported that trial met primary endpoint, noted October 24, 2022.
| 0 |
CGEN
|
Platinum resistant ovarian cancer
|
Phase 1/2
|
2023-06-05 00:00:00
|
Phase 1/2 data presented at ASCO reported an objective response rate (ORR) of 2/9 [22%] pts; 2 pts with SD. Disease control rate [CR + PR + SD] 4/9 [44%], noted June 5, 2023.
| 1 |
AMGN
|
Asthma
|
Approved
|
2021-12-17 00:00:00
|
Approved December 17, 2021.
| 1 |
ELDN
|
Amyotrophic Lateral Sclerosis
|
Phase 2a
|
2022-05-31 00:00:00
|
Phase 2a topline data showed that treatment met the primary endpoints of safety and tolerability. Adverse events were equally distributed across dose levels, noted May 31, 2022.
| 1 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.